The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM)

被引：50

作者：

Basile, Jan N. ^{[1
]}

机构：

[1] Med Univ S Carolina, Seinsheimer Cardiovasc Hlth Program, Charleston, SC 29425 USA

来源：

JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2013年 / 27卷 / 03期

关键词：

INADEQUATE GLYCEMIC CONTROL; DOUBLE-BLIND; BODY-WEIGHT; ADD-ON; DAPAGLIFLOZIN; MELLITUS; CANAGLIFLOZIN; METFORMIN; INSULIN; HYPERGLYCEMIA;

D O I：

10.1016/j.jdiacomp.2012.12.004

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Type 2 diabetes mellitus (T2DM) significantly increases morbidity and mortality from cardiovascular disease (CVD). Treatments for patients with T2DM have the potential to reduce cardiovascular (CV) risk. This review focuses on the potential of a new class of antidiabetic agents, the sodium glucose cotransporter 2 (SGLT2) inhibitors, to reduce CV rsk in patients with T2DM through reductions in hyperglycemia, blood pressure (BP), and body weight. The results of clinical trials of SGLT2 inhibitors are summarized and discussed. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：280 / 286

页数：7

共 72 条

[1]

[Anonymous], J AM SOC NEPHROLOGY

[2]

[Anonymous], DIABETOLOGIA

[3]

[Anonymous], 2012, Diabetes Care, DOI DOI 10.2337/DC12-S004

[4]

[Anonymous], 2011, National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States

[5]

[Anonymous], 2011, 202293 FDA NDA

[6] Renal glucose reabsorption inhibitors to treat diabetes [J].

Bailey, Clifford J. .

TRENDS IN PHARMACOLOGICAL SCIENCES, 2011, 32 (02) :63-71

[7] Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial [J].

Bailey, Clifford J. ;

Gross, Jorge L. ;

Pieters, Anne ;

Bastien, Arnaud ;

List, James F. .

LANCET, 2010, 375 (9733) :2223-2233

[8] A New Approach to Glucose Control in Type 2 Diabetes: The Role of Kidney Sodium-Glucose Co-transporter 2 Inhibition [J].

Basile, Jan .

POSTGRADUATE MEDICINE, 2011, 123 (04) :38-45

[9]

Beest FJAP, 2008, CURR MED RES OPIN, V24, P2523, DOI [10.1185/03007990802336335, 10.1185/03007990802336335 ]

[10] Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin [J].

Bolinder, Jan ;

Ljunggren, Osten ;

Kullberg, Joel ;

Johansson, Lars ;

Wilding, John ;

Langkilde, Anna Maria ;

Sugg, Jennifer ;

Parikh, Shamik .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) :1020-1031

← 1 2 3 4 5 6 7 8 →